公开(公告)号：US20210052600A1

公开(公告)日：2021-02-25

申请号：US16958394

申请日：2018-12-27

申请人： Takeda Pharmaceutical Company Limited

发明人： Izumi Kamo ,  Nele MUELLER-PLOCK

IPC分类号： A61K31/553 ,  A61K31/55 ,  A61P1/00 ,  A61P13/00

摘要： The present invention provides a medicament for use in treating stress urinary incontinence with fewer adverse effects including a body weight lowering effect. The present invention also provides a medicament for use in treating a disease such as incontinence of feces and further provide a medicament for use in treating a disease such as incontinence of feces with fewer adverse effects including a body weight lowering effect.
A medicament for use in treating stress urinary incontinence, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug. A medicament for use in treating incontinence of feces, etc., comprising a 5-HT2C receptor agonist. A medicament for use in treating incontinence of feces, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug.